Context: Polymorphisms in genes involved in regulation, biosynthesis, metabolism, and actions of testicular sex hormones may influence hormone balance and phenotype of aging men.
T
he aging of men is affected by gender-specific environmental and lifestyle factors, such as obesity, physical activity, smoking, and alcohol consumption (1) (2) (3) . However, the most conspicuous gender differences are the lifelong exposure of men to testicular androgens and of women to ovarian estrogens. Unlike women, men have a lifelong exposure to androgens and do not experience a sudden cessation of gonadal function comparable to menopause. Cross-sectional and longitudinal population studies demonstrate that although most hormones with anabolic actions (e.g. GH, IGF-I, and dehydroepiandrosterone) decrease in healthy men progressively with aging, the decline of testicular testosterone (T) production is gradual, with large interindividual variability (1, 3) . The average decline of serum total T between ages 20 and 80 yr is 35%, and the concomitant decline of the biologically active free fraction of T is 50%; moreover, the reference range is large in serum gonadotropins (1-10 IU/liter) and T [2.9 -8.6 g/liter (10 -30 nmol/liter)]. The aging-related decline in T levels is mainly due to primary Leydig cell failure but can also be combined with a decline of gonadotropin secretion associated with obesity and comorbidities (3) . However, the prevalence of late-onset hypogonadism, defined as the decline of T levels with associated symptoms, remains unknown; apparently, only a minority of men become truly hypogonadal with aging (1) (2) (3) .
Multiple hereditary (polymorphisms, race), lifestyle, environmental (obesity, diet, stress), socioeconomic (education, income, living conditions), somatic, psychological, and health (including drugs) factors contribute to the large interindividual variability of the basal activity and age-related decline of the pituitary-gonadal function in men (3, 4) . Limited information is currently available on polymorphisms in genes affecting the regulation, production, actions, and metabolisms of androgens (5, 6) . Therefore, in the present study, we genotyped selected polymorphisms in nine genes [AR (androgen receptor), ESR1 and ESR2 (estrogen receptor-␣ and -␤), SRD5A2 (steroid 5␣-reductase type II), CYP17A1 (17␣-hydroxylase/17,20-lyase), CYP19A1 (aromatase), sex hormone-binding globulin (SHBG), LHB (LH ␤-subunit), and LHCGR (LH receptor)] shown previously to have phenotypic effects and related them to the production or action of androgens and estrogens in a cohort of middle-aged and elderly European men. Their associations with circulating levels of selected hormones, alterations upon aging, and phenotypic effects were assessed.
Subjects and Methods

Subjects
Subjects included in the analyses are participants in the European Male Aging Study (EMAS), a multicenter populationbased study of the determinants of male aging. A total of 3369 community-dwelling men aged 40 -79 yr were recruited from eight European centers: Florence (Italy), Leuven (Belgium), Lodz (Poland), Malmö (Sweden), Manchester (UK), Santiago de Compostela (Spain), Szeged (Hungary), and Tartu (Estonia). Ethical approval was obtained at each center, and participants gave informed consent. Further details on the study design and methodology used in EMAS can be found in Ref. 7 . The ethnic background of the men was almost exclusively European (with the exception that at least one parent or grandparent of 21 men was born outside Europe).
Blood sampling and processing
A single sample of morning fasting venous blood (taken before 1000 h) was processed and stored according to standard protocols and used for hormone, hematological, and biochemical measurements, as well as for DNA extraction using the phenol:chloroform method. A total of 2981 subjects consented to extraction and genetic analysis of their DNA.
Genetic analysis
Celera and dbSNP single nucleotide polymorphism (SNP) databases were searched for SNPs with a minor allele frequency (MAF) of at least 5% for AR, CYP17A1, CYP19A1, ESR1, ESR2, LHB, LHCGR, SHBG, and SRD5A2. Most of the SNPs and other polymorphisms in these genes selected for genotyping have previously been shown to influence the balance of male pituitary-testicular hormones (5, 6) . This resulted in a total of 39 SNPs, two repeats (TA repeat in SRD5A2 and TAAAA repeat in SHBG), one insertion/deletion (indel) (TCT in CYP19A1), and a variant (V) in LHB being genotyped (Table 1) .
SNPs were genotyped with MALDI (matrix-assisted laser desorption/ionization)-TOF (time-of-flight) mass spectrometry using Sequenom MassARRAY technology following the manufac-turer's instructions (www.sequenom.com). Genotyping of the SHBG repeat, SRD5A2 repeat, and the CYP19A1 indel was described previously (8) . Genotyping of V-LHB was based on differential immunoreactivity of wild-type (WT) and V forms of LH in serum samples, as described before (9) . One of the assays detects both WT-and V-LH, the other only WT hormone. The ratio of assays WT/WTϩV correlates with the LHB genotype (Ͼ1 WT/WT, 0.5 WT/V, 0 V/V).
Quality control thresholds for samples and assays were set to 90%. Polymorphisms were tested for deviation from Hardy-Weinberg equilibrium in the population and excluded if P Յ 0.01.
Allele frequencies were also compared with HapMap data or the literature, where possible, to check for consistency.
Linkage disequilibrium (LD; i.e. nonrandom association of alleles) was assessed for each gene. The LD between SNPs was determined by pairwise comparisons of r 2 (correlation coefficient between SNPs; if r 2 ϭ 1, SNPs predict one another) and DЈ (likelihood that recombination has occurred between SNPs; if DЈ ϭ 1, no recombination has occurred) using Haploview (Broad Institute, Cambridge, MA) version 3.32 (10) . LD between SNPs and multiallelic markers was determined using Helixtree (Statistics.com, Bozeman, MT). 
Hormone assays
Each serum sample was assayed for T, estradiol (E 2 ), LH, FSH, and SHBG. LH, FSH, and SHBG were measured as described previously (3, 7) . T and E 2 were measured using gas chromatography-mass spectrometry as described before (11, 12) . The lower limit of quantification of T was 170 pmol/liter, and of E 2 , 2.2 pmol /liter. The intra-and interassay coefficients of variation in T measurements were 2.9 and 3.4%, and in E 2 measurements, 6.4 and 10.1%, respectively. Free and bioavailable (non-SHBG-bound) T and E 2 levels were derived using the total hormone measurement, and levels of SHBG and albumin using mass action equations and association constants (13, 14) . LH ϫ T product was calculated by multiplying LH and total T levels and E 2 /T ratio from total T and total E 2 levels.
Measures of health status
Height, weight, body mass index (BMI), waist circumference, and waist-hip ratio were assessed as previously described (7). Skinfold thicknesses and body circumferences were used to calculate the percentage of body fat (15) . Routine hematological and biochemical markers were measured using standardized methods under good laboratory practice conditions in internationally and/or nationally accredited hospital laboratories in each center (7) . Hematology analyses included hemoglobin, platelet, and red and white cell counts. Biochemical measurements included glucose, albumin, cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and low-density lipoprotein cholesterol [calculated from total and HDL cholesterol, and fasting triglycerides using the Friedewald equation (16)]. Insulin levels were measured at a single laboratory using an ELISA assay (17) . The homeostasis model assessment was used to estimate insulin resistance (HOMA-IR), sensitivity (HOMA-S), and pancreatic ␤-cell function (HOMA-B) (18) . The quantitative insulin sensitivity check index (QUICKI) was calculated (19) . Prostatic symptoms were assessed using the International Prostate Symptom Score (IPSS) questionnaire (20) and the risk of prostatic cancer by measuring serum prostate-specific antigen (PSA). Sexual and cognitive functions were assessed as described before (7).
Statistical analyses
In the analysis hormone levels, hematology, biochemistry, lipids, measures of insulin sensitivity, PSA/IPSS levels, and cognitive tests were treated as continuous variables. Measures of sexual dysfunction were dichotomized. Erectile dysfunction was defined as the inability to reach and keep an erection good enough for sexual intercourse in the last 4 wk (never/sometimes vs. usually/always) (21) . Poor morning erection was defined as the frequency of morning erections in the last 4 wk (none/Ͻ1 per month vs. 2-3 per month or more), and poor libido was defined as loss of interest in sex in the last 4 wk (completely/much less interested vs. less interested/no change). Because the six repeats allele of the SHBG TAAAA repeat reportedly reduces transcriptional activity (22) , this polymorphism was dichotomized into six repeats allele vs. at least seven repeats allele. Only two alleles were present for the SRD5A2 TA repeat, zero repeats and nine repeats, so it was dichotomized into zero repeats allele vs. nine repeats allele.
Linear regression was used to test for association between each of the endocrine factors and genotypes for each polymorphism. The difference in mean levels of each hormone and SHBG was estimated for subjects with one copy of the minor allele and subjects with two copies of the minor allele compared with subjects with zero copies. Results are adjusted for age and center and reported as the adjusted mean values of the endocrine factors for a subject of mean age (60 yr) living in center 1 (Florence). Results are also reported as differences (␤-coefficients) and 95% confidence intervals (CI). The SE values were corrected to account for differences between centers. To reduce the chance of false-positive findings, only associations with P Յ 0.01 were prioritized for further analysis. Polymorphisms associated with endocrine factors were subsequently tested for association with measures of health status: anthropometry, hematology, biochemistry and lipid measures, insulin action, and sexual, prostate, and cognitive function. Because the measures of sexual dysfunction were dichotomous variables, logistic regression was used, with results reported as odds ratios and 95% CI. Interactions between genes found to be associated with hormone levels were assessed by fitting interaction terms between the relevant SNPs. To further explore the impact of center, interaction terms were fitted between polymorphism and center to determine whether the association observed differed across centers. Statistical analysis was performed using STATA version 9.2 (http://www.stata.com).
Results
The study population
Of the 2981 DNA samples of the EMAS cohort genotyped, 233 were excluded from the analysis due to failing sample quality control. The analysis was conducted on the remaining 2748 subjects. The SNP and repeat polymorphisms detected in the AR, CYP17A1, CYP19A1, ESR1, ESR2, LHB, LHCGR, SHBG, and SRD5A2 genes are presented in Table 1 . All SNPs were in HardyWeinberg equilibrium (P Ͼ 0.01). Subject characteristics have been partly published before (7, 8, 23) and are presented in Supplemental Table 1 , published on The Endocrine Society's Journals Online web site at http:// jcem.endojournals.org.
Influence of SHBG polymorphisms
We genotyped three SHBG polymorphisms, a TAAAA repeat polymorphism in the promoter region, a G 3 A polymorphism (rs1799941) in intron 1, and a nonsynonymous G 3 A polymorphism (rs6259) in exon 8 (Asp356Asn). None of these SNPs were associated with age. The repeat polymorphism was associated with serum levels of SHBG, total E 2 , total T, and the LH ϫ T product (Table 2) ; in each case, shorter repeats were associated with higher levels of these hormonal parameters, and the effects were greater in variant homozygotes than heterozygotes. The A allele of the intron 1 polymorphism (rs1799941) was highly significantly associated with higher serum SHBG, total E 2 , total T, and LH ϫ T product. The association with higher serum LH was less marked, with only the variant homozygotes reaching statistical significance. The findings with the two polymorphisms were similar, owing to the high level of LD between them (r 2 ϭ 0.89). The minor A allele of the exon 8 SNP (rs6259) was associated with higher free T, but it only reached significance when comparing variant heterozygotes (GA) to common homozygotes (GG). The association between the polymorphism in intron 1 (rs1799941) and LH ϫ T product significantly differed across centers (P ϭ 0.048). Florence, Santiago, and Tartu showed a significantly different effect in heterozygotes compared with the other five centers. This was the only significant difference detected between the centers.
No associations (i.e. P Ͻ 0.01) were observed between SHBG polymorphisms and nonhormonal phenotypes including anthropometric parameters (height, weight, BMI, waist circumference, waist-hip ratio, percentage body fat), hematology (hemoglobin, platelets, blood pressure), laboratory parameters of metabolic function (total, low-density lipoprotein-and HDL-cholesterol, triglycerides, IPSS), PSA, measures of insulin sensitivity/resistance (HOMA-IR, HOMA-B, HOMA-S,  QUICKI) , sexual function (erectile dysfunction, morning erection, loss of libido), or with cognitive outcomes (results not shown).
Influence of AR, ESR1, and ESR2 polymorphisms
In our previous report, the common AR CAG repeat polymorphism in exon 1 showed significant association with higher circulating T and E 2 in the current study population (23) . We now assessed the associations of a G 3 A SNP (rs6152) in exon 1 and four SNPs (Table 1) in intron 1 of AR. Because of a very strong LD (r 2 Ͼ 0.97) for all pair-wise comparisons, we only present the data on the rs6152 polymorphism (the findings with the others were very similar). There was no association with age. The minor allele of the polymorphism was significantly associated with lower serum total E 2 , free E 2 , and bioavailable E 2 (Table 3) .
Four and three SNPs were genotyped for the two estrogen receptor genes, ESR1 and ESR2, respectively (Table 1) . There was no association between these SNPs and age. One ESR2 SNP (rs1256031) showed significant association with lower E 2 /T ratio, but only when comparing variant homozygotes to common homozygotes (Table 3) . The results did not significantly differ between the centers. No associations (i.e. P Ͻ 0.01) were observed with the nonhormonal parameters.
Influence of LHB and LHCGR polymorphisms
Two LHB polymorphisms were determined, a 3Ј-untranslated region (UTR) C 3 T SNP (rs2013040), and an exon 2 Trp8Arg/Ile15Thr polymorphism, also defined as V-LH (9, 24). There were no associations with age. The former SNP showed significant association with higher serum levels of free E 2 , bioavailable E 2 , and E 2 /T ratio (Table 3 ). However, due to its rarity (MAF ϭ 0.04), these results must be cautiously interpreted. The MAF of the V-LHB allele in the different European centers ranged from 7.34% in Szeged to 11.8% in Tartu (P Ͻ 0.05), in agreement with a previously documented north-south gradient in its frequency (9) . The V allele was significantly associated with lower LH levels ( Table 3) .
The LHCGR SNP (rs654061), present in intron 4 (Table 1), was associated with lowered E 2 /T ratio but with significance only in variant homozygotes (Table 3) . No associations (i.e. P Ͻ 0.01) were observed with any of the other nonhormonal phenotypes, neither were there differences between centers (except for V-LHB; see above).
Influence of CYP17A1 and SRD5A2 polymorphisms
Neither of the two CYP17A1 polymorphisms determined (Table 1) showed significant associations with age, hormones, or the nonhormonal parameters determined.
Five polymorphisms of the SRD5A2 gene were genotyped, four of them SNPs in the 5Ј-UTR, exon 1 and introns 2 and 3, and one being a TA repeat in exon 5 ( Table  1) . Of these, the intron 3 A 3 G SNP (rs7571644) was associated with higher bioavailable T only in homozygotes [mean bioavailable T level ϭ 8.27 nmol/liter; 95% CI, 7.60, 8.93 for GG genotype (n ϭ 31, 1.1%) vs. 7.33 nmol/liter; 95% CI, 7.13, 7.53 for AA genotype (n ϭ 2113, 66.3%); P ϭ 5.00 ϫ 10
Ϫ3
]. Likewise, long TA repeats of exon 5 (9/9 vs. 0/0) were associated with higher bioavailable T, but only in homozygotes [mean bioavailable T level ϭ 8.22 nmol/liter; 95% CI, 7.55, 8.90 for 9/9 genotype (n ϭ 30, 1.1%) vs. 7.32 nmol/liter; 95% CI, 7.12, 7.51 for 0/0 (n ϭ 2187, 80.5%) genotype; P ϭ 8.01 ϫ 10 Ϫ3 ]. These associations did not differ by center.
No associations were observed with the nonhormonal parameters including PSA and IPSS.
Influence of CYP19A1 polymorphisms A total of 14 polymorphisms, located in the 5Ј-UTR, introns 1, 2, and 4, and in the 3Ј-UTR of CYP19A1, were genotyped (Table 1) . No associations with age were observed. Several associations were observed with serum hormone levels ( Table 4 and Fig. 1 ). The indel TCT in intron 4 (rs1157899) was significantly associated, in variant homozygotes only, with higher free T. A similar association was observed with the GG form of the T 3 G SNP (rs727479) in intron 2; the LD between the SNP and indel was 0.93. Figure 1 shows the association of the CYP19A1 polymorphisms with circulating E 2 levels. The 3Ј-UTR T 3 C SNP (rs10046), intron 4 TCT indel (rs11575899), and two intron 2 SNPs (rs2414096 and rs727479) were b Results were very similar for all AR SNPs, so only rs6152 is presented because they are in very strong LD (r 2 Ն 0.097) for all pair-wise comparisons.
associated with lower E 2 . Associations with higher serum E 2 were observed with three SNPs present in intron 1 (rs10519299, rs12050767, and rs749292). The minor alleles of these three SNPs are in strong LD with the common alleles of the other associated SNPs in the block (rs10046 and rs2414096) and therefore represent the same effect. Associations were also observed between CYP19A1 polymorphisms and measures of insulin resistance (Table 4) . Strongest was the association between the 3Ј-UTR T 3 C SNP (rs10046) and higher levels of HOMA-IR. No associations (i.e. P Ͻ 0.01) were observed with any of the other nonhormonal phenotypes. None of these associations differed by center.
Additional data are presented on associations with the hormonal (Supplemental Table 2 ) or phenotypic (Supplemental Table 3 ) parameters at borderline level of significance (0.01 Ͼ P Ͻ 0.05). There was no evidence of any epistatic effects between genes associated with hormonal parameters.
Discussion
In this large population-based study of middle-aged and elderly European men, we found significant associations between genes related to pituitary-testicular endocrine function and circulating reproductive hormone levels measured using state of the art gas chromatography-mass spectrometry techniques. The availability of extensive clinical and laboratory measurements gave us the opportunity to look for detailed and robust genotypic/phenotypic correlations.
Relatively little is known about the influence of genetic polymorphisms on function of the hypothalamic-pituitary-testicular axis. Twin studies have demonstrated that genetic factors account for more than 50% of the variability on male serum gonadotropin, sex steroid, and SHBG levels (25, 26) . With respect to individual genes, the most extensively studied single genetic variant is the AR exon 1 CAG repeat (23, 27) . Only minor effects of this polymorphism on circulating T and E 2 levels are apparent, reaching statistical significance with large sample sizes. We have reported previously from the EMAS cohort associations of the AR exon 1 CAG repeat polymorphism with endocrine and metabolic parameters (23) , and of AR exon 1 CAG repeat and other polymorphisms with heel ultrasound parameters (8) . Other genes with polymorphisms associated with androgen and/or estrogen levels in men include SHBG (28), CYP17 (29) , CYP19A1 (30), 17␤HSD5 (31) , and uridine diphosphate glucuronyltransferase 2B7 (UGT2B7) (32) , but many potentially important polymorphic influences have apparently not yet been identified.
The polymorphisms genotyped in SHBG had multiple effects. Besides the cognate protein, circulating levels of LH, total and free T, total E 2 , and the LH ϫ T product were affected. The Asp356Asn (GAC 3 AAC) mutation in exon 8 of SHBG (rs6259) induces an additional consensus site for N-glycosylation, increasing circulatory half-life of the variant SHBG protein without affecting its steroid-binding affinity (33) or steady-state plasma levels (34), which our findings confirmed. Variable associations of this polymorphism, depending on age of men, were recently reported between SHBG and T levels (35) . The only significant association we found with this polymorphism was the slightly but significantly (P Ͻ 0.01) elevated level of free T in heterozygotes. The other two SHBG polymorphisms, a TAAAA repeat in the promoter region and G 3 A transversion in intron 1 (rs1799941), had high LD (r 2 ϭ 0.89) as previously shown (36), with consequent similar correlations with hormone levels. Short repeats, i.e. (TAAAA) 6 , were associated with higher serum levels of SHBG, total T and E 2 , and higher LH ϫ T product. In addition, higher LH levels were associated with AA genotype of the rs1799941 polymorphism. Higher SHBG levels are thus associated with the expected higher total, but not free, T and E 2 levels. Although in vitro studies have shown that the (TAAAA) 6 allele reduces SHBG gene expression (22) , opposite in vivo findings in men are consistent. Our findings confirm the three previous findings on higher SHBG levels in association with shorter TAAAA repeats (28, 34, 35) , but not a very recent finding on their association with rs6259 (37) .
The association of the two CYP19A1 polymorphisms (rs11575899 and rs727479) with lower E 2 levels and elevated levels of free and bioavailable T matches well because the potent negative feedback action of E 2 on LH secretion should be suppressed, resulting in elevated T level (38) . However, we did not find increased LH levels in men with these SNPs, probably due to insufficient effect size and/or high variability in levels of this hormone. We have reported previously in the EMAS cohort moderate to strong associations between CYP19A1 polymorphisms and bone ultrasound density in a LD block spanning from intron 1 to the 3Ј-UTR (8). Our current finding that the same polymorphisms (rs10519299, 12050767, and 749292) are also positively associated with serum E 2 levels agrees with a very recent study showing similar association with higher E 2 levels and lumbar spine BMD (30) . These studies strengthen the contention that genetic variability in CYP19A1 significantly affects circulating E 2 levels and consequent BMD. Two SNPs in ESR1 were found in our previous study to affect BMD, but not circulating E 2 levels (8). In the current study, only one ESR2 polymorphism had a mild effect on the LH ϫ T product. Hence, on the basis of this limited analysis, the genetic variability of aromatase has greater influence on circulating sex hormone levels than that of estrogen receptors.
The common V-LH␤ (Trp   8   Arg/Ile   15 Thr) differs functionally from WT-LH, predisposing its carriers to mild but significant alterations in reproductive function, such as subfertility, polycystic ovary syndrome, and delayed tempo of puberty (9) . In a group of independently living elderly men, a significant positive correlation between fat mass and serum leptin level was only observed in heterozygous carriers of V-LHB (39) . The variant allele is transcriptionally more active than WT-LHB due to additional differences in its promoter sequence, and there are qualitative and quantitative differences in LH action in carriers of V-LHB (9). The significantly lower LH level in carriers of V-LHB agrees with the previously documented shorter circulatory half-life of V-LH (9) . The other LHB polymorphism, a C 3 T change in the 3Ј-UTR, in heterozygotes showed a borderline correlation with higher total and free E 2 levels. Due to the low MAF (0.04), these findings must be interpreted with caution. Several polymorphisms have also been described in LHCGR (24) . We determined five of these, but only one, rs654061 in intron 4, showed association with lowered E 2 /T ratio in homozygotes.
Besides the widely studied AR CAG repeat in exon 1 there are multiple SNPs in this gene (27) . After our previous report on significant association of the CAG repeat length with serum T and E 2 levels in the EMAS cohort (23), we now genotyped five SNPs (one in exon 1, four in intron 1). Because of high LD, the phenotypic correlation was similar in all five SNPs, i.e. a negative association with circulating E 2 (total, free, bioavailable). Intriguingly, the major allele of rs6152 (G), associated with higher E 2 levels, is strongly associated with male-pattern baldness (40) and higher-grade prostate cancer (41) . Although the connection of the latter associations with altered circulating estrogen levels is hypothetical, altered estrogen/androgen ratio may be involved.
Polymorphisms in SRD5A2 have been associated with risk of prostate cancer, but the biochemical evidence for their relationship with androgen levels is controversial (42) . Unlike some findings on effects of the V89L polymorphism (rs523349) (43, 44) we could not confirm associations with serum androgen levels. Instead, the intron 3 C 3 A SNP (rs7571644) and the long form of the TA repeat polymorphism in 3Ј-UTR (0/0 vs. 9/9) were weakly but significantly (P Ͻ 0.01) associated with increased levels of bioavailable T. It is apparent that SRD5A2 polymorphisms are not a major determinant of circulating T and E 2 levels.
In this analysis, we did not exclude subjects who were taking medications that affect hormone levels. However, when we subsequently tested the effect of such exclusion, it made no difference to the results. Given that this study recruited subjects from eight European countries, one might expect some variation between the different populations. Indeed, there were some statistically significant differences in both allele frequencies and hormones between some study centers. In the analysis, we included the data from all centers in the regression models and calculated corrected SE values to account for any center differences. We then fitted interaction terms to the models to further explore the influence of center. The associations observed were the same in all centers, apart from the association between the polymorphism in intron 1 of SHBG (rs1799941) and LH ϫ T product, which differed very modestly (P ϭ 0.048) in Florence, Santiago, and Tartu compared with the other five centers.
In conclusion, we found several associations of genetic polymorphisms in genes related to sex hormone production with parameters of hormonal balance of men, but only mild effects were observed at the secondary phenotypic level. Although the variability of sex hormone and SHBG levels is under strong genetic influence, the complex interactions between multiple genes and environment apparently dilute these responses to the extent that only a few of them are discernible at the phenotypic level.
